DIR Return Create A Forum - Home
---------------------------------------------------------
Road2HardCoreIron
HTML https://road2hardcoreiron.createaforum.com
---------------------------------------------------------
*****************************************************
DIR Return to: Anabolic Steroids News
*****************************************************
#Post#: 559--------------------------------------------------
Andriol. Primobolan question?
By: Road2HardCoreIron Date: March 13, 2022, 11:46 am
---------------------------------------------------------
those who do not want to inject testosterone Andriol Testo caps
have been updated keep in mind there are on going and many
studies. You no longer have to keep them in the fridge. This
drug can not be counterfeit by anyone. Yes you still will have
to take 5-6 caps spread out twice a day. The new improve is much
better absorb. Great gor bridging or break in between cycles as
well. It s much like primo tabs it is not 17 alk. Therefore very
easy on liver. I might Spencer someone to cycle this with a
primo cycle to see if Andriol androgen is enough for primobolan
to cling to its androgen receptors. To allow primo to Do its
job. I have not seen any studies in the to. But I know how
important it is to have a test base when running primo.
Abstract
Objective: The objective of this study was to document the
efficacy and tolerability of the new formulation of Andriol
Testocaps in the treatment of late-onset hypogonadism in a
clinical practice setting.
Methods: The primary inclusion criterion was symptomatic
testosterone deficiency, as confirmed by laboratory testing
(morning total testosterone <12 nmol/L) on two separate
occasions. The study was performed in 43 centres in Austria and
a dosage of oral testosterone undecanoate of 2 x 80 mg/day was
used for three months. The ADAM questionnaire, the AMS scale and
the SF-36 questionnaire were administered by the patients and
specific questions were asked to the prescribers.
Results: A total of 189 patient report forms and 185 doctor
report forms were completed. The average age of the participants
was 54.7 +/- 12.3 years and average treatment duration was 13.9
+/- 2.2 weeks. Serum testosterone level increased by more than
50% from 8.7 +/- 4.3 nmol/L to 13.2 +/- 6.7 nmol/L (p < 0.001).
Treatment improved symptoms on the ADAM and AMS scales, whereas
no changes were observed on the SF-36. There were no significant
effects on serum PSA levels.
Conclusion: Short-term treatment with oral testosterone
undecanoate in a clinical practice setting improved late-onset
hypogonadism symptoms in aging men with low testosterone levels.
Last edited: A moment ago
*****************************************************